AIMEE COCKERHAM: Open Payments
NPI 1669086096 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,429 in 63 payments from 14 companies in 2025. Trend: 2023 $425 · 2024 $258 · 2025 $1,429
Food & beverage: $1,429
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $238 |
| ABBVIE INC. | 13 | $228 |
| Phathom Pharmaceuticals, Inc. | 8 | $218 |
| Gilead Sciences, Inc. | 3 | $125 |
| QOL Medical, LLC | 4 | $93 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $84 |
| Madrigal Pharmaceuticals | 4 | $82 |
| Janssen Biotech, Inc. | 4 | $74 |
| Lilly USA, LLC | 4 | $67 |
Products named: ENTYVIO, VOQUEZNA, RINVOQ, Sucraid, DUPIXENT, XIFAXAN, REZDIFFRA, TREMFYA.
Industry payments across MS — which companies pay providers there.
